Home / Peptides
July 21, 2026
8 min read
Emideltide
Saaim Khan
Harvard Medical
Key Takeaways
- Emideltide, also known as delta sleep-inducing peptide or DSIP, is commonly described as a short sleep-related peptide, but the main point for readers is that the science is still unsettled.
- It is purported to support sleep regulation and has also been evaluated for opioid withdrawal and narcolepsy, but FDA's current review found that the available clinical evidence is insufficient and that no data support the nominated subcutaneous route for chronic insomnia, narcolepsy, or opioid withdrawal.
- The older literature includes small exploratory studies and mechanistic/nonclinical signals related to sleep architecture and opioid-dependent pathways, but that does not make emideltide a proven treatment for insomnia, withdrawal, narcolepsy, or general sleep optimization.
- Emideltide is therefore best described as investigational, unapproved, and scientifically unresolved, with important identity, formulation, route, effectiveness, and safety uncertainties that should remain visible before any patient-facing benefit language.
[FDA, 2026; Schneider-Helmert et al., 1981; Schneider-Helmert and Schoenenberger, 1983; Dick et al., 1984; Backmund et al., 1998].
The compound name for delta sleep-inducing peptide (DSIP) – a nonapeptide with the canonical sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) and no validated modern regulatory approval or clinically established therapeutic indication.
Emideltide at-a-glance evaluation
| Dimension | Scientific scope |
|---|---|
| FDA-approved indication(s) | None identified. Currently classified as an unapproved peptide under forthcoming FDA compounding review, not an approved drug. [Reuters, 2026; Washington Post, 2026] |
| Compound status | Historical neuropeptide/nonapeptide usually referred to in the literature as DSIP; emideltide appears to be the contemporary name used in the current U.S. peptide compounding-review context. [Kovalzon and Strekalova, 2006; Reuters, 2026] |
| Strongest evidence | Historical animal neurophysiology/pharmacology and review-level synthesis; limited, older exploratory human sleep, anesthesia-adjunct, endocrine, and opioid-detox literature. [Kovalzon and Strekalova, 2006] |
| Key distinctions | Historical endogenous/hypothesized DSIP biology ≠ synthetic exogenous DSIP/emideltide ≠ phosphorylated or otherwise modified DSIP analogs ≠ market claims about sleep, detox, stress, or recovery. [Kovalzon and Strekalova, 2006] |
| Permissible framing | "Investigational," "historically studied," "predominantly preclinical," "older exploratory human literature exists," "being discussed in FDA compounding-review context," "human therapeutic efficacy has not been established." [Reuters, 2026; The Guardian, 2026] |
| Impermissible framing | "FDA-approved," "clinically proven for insomnia," "established opioid-withdrawal treatment," "validated sleep peptide," "safe and effective," "modern evidence-based sleep or addiction therapy." [Reuters, 2026; The Guardian, 2026] |
| Trigger to revisit | Public release of FDA briefing materials and written recommendation after the July 2026 PCAC meeting; any FDA follow-on action; any retrievable modern phase-based emideltide/DSIP clinical program or peer-reviewed same-molecule PK/safety trial. [Reuters, 2026; Washington Post, 2026] |
Product overview
Identity
Delta sleep-inducing peptide was originally described as a naturally occurring rabbit-derived nonapeptide associated with delta-EEG activity, and the canonical sequence repeatedly attached to DSIP in the literature is WAGGDASGE. Its molecular weight is generally described at roughly 850 Da. The contemporary name emideltide appears in current regulatory/journalistic reporting, while the historical scientific literature overwhelmingly uses DSIP or delta sleep-inducing peptide. [Schoenenberger et al., 1977; Kovalzon and Strekalova, 2006; Reuters, 2026].
Molecule confusion
The 2006 review explicitly presents DSIP as an unresolved problem: source biology is unclear, no clinically validated receptor-target framework exists, and some observations may reflect DSIP-like immunoreactivity, carrier-bound forms, precursor-related material, or analog behavior rather than a straightforward endogenous-to-exogenous therapeutic pathway. [Kovalzon and Strekalova, 2006].
| Material | What it is | Why it cannot be collapsed into "emideltide" |
|---|---|---|
| Historical DSIP | The original nonapeptide described in rabbit sleep-transfer work and later experimental literature | Historical endogenous/discovery context does not itself prove modern exogenous drug efficacy. [Schoenenberger et al., 1977; Kovalzon and Strekalova, 2006] |
| Synthetic DSIP | Experimental exogenous peptide used in older animal and human studies | Same sequence does not erase route, formulation, manufacturing, or study-quality differences. [Kovalzon and Strekalova, 2006] |
| Emideltide | Current name used in 2026 peptide compounding-review reporting | Current naming/regulatory attention does not create an approved product or modern efficacy dataset. [Reuters, 2026] |
| Modified / phosphorylated DSIP analogs | Stability- or activity-modified variants in later animal literature | Analogue findings should not be presented as same-molecule proof for native emideltide/DSIP. [Kovalzon and Strekalova, 2006] |
Mechanism of action
Historical literature proposed several pathways: modulation of slow-wave sleep circuitry, interaction with NMDA-linked neuronal processes, α1-adrenergic involvement in pineal acetyltransferase effects, links to glucocorticoid-induced leucine zipper (GILZ) and MAPK-related signaling, and broader endocrine/stress-modulating activity. But none of that has matured into a clinically validated human mechanism. [Kovalzon and Strekalova, 2006].
The tissue- and endpoint-level evidence is also heterogeneous. DSIP has been studied in sleep neurophysiology, endocrine regulation, pain, stress/hypoxia, seizure models, and older psychiatry/endocrine biomarker contexts. That breadth can sound impressive, but scientifically it often means the opposite: a long list of exploratory observations without a single modern, validated drug-development axis. [Kovalzon and Strekalova, 2006].
Pharmacology
A recurring limitation is poor pharmacologic definition. Historical review literature describes low in-vitro molecular stability, with degradation on the order of minutes and a proposed role for carrier proteins or precursor association in vivo. Modern human PK, exposure-response, receptor occupancy, validated metabotyping, and dose-ranging data were not identified in current indexed reporting. So any claims about onset, duration, bioavailability, or route equivalence would be overreach. [Kovalzon and Strekalova, 2006].
A note on tense and certainty
In preclinical contexts, write "in rabbits," "in rats," "in mice," "older experimental literature reported," or "the 2006 review summarized" rather than "emideltide improves sleep" or "emideltide treats withdrawal." In historical human contexts, write "older exploratory human reports described…" rather than "clinical trials proved…" Reserve verbs like improves, reduces, or normalizes only for the result inside a cited experiment, not as a patient-facing property of the peptide. [Kovalzon and Strekalova, 2006; Reuters, 2026].
Common forms in circulation
In current reporting, the relevant public-facing name is emideltide; in historical literature, the common scientific label is DSIP. Gray-market/wellness discussion treats it as an injectable sleep or recovery peptide, but contemporary reporting emphasizes that the broader peptide category is being promoted in wellness settings despite thin evidence and unresolved safety/quality questions. [Reuters, 2026; The Guardian, 2026].
Names, aliases, and stack pairings to flag
Relevant names include Emideltide, DSIP, and delta sleep-inducing peptide. Common market-adjacent narrative pairings are likely to involve sleep, stress, recovery, anti-aging, or detox language; these should be treated as market framing, not evidence-backed therapeutic positioning. [Kovalzon and Strekalova, 2006; Reuters, 2026].
Evidence base
The evidence ladder is unusually important here because emideltide's story spans discovery-era neuropeptide biology, small-animal physiology, older exploratory human reports, and modern peptide-market enthusiasm.
| Evidence tier | What qualifies | What it does not justify |
|---|---|---|
| Historical / exploratory human study | Older human sleep, anesthesia-adjunct, endocrine, psychiatry, or opioid-detox reports involving DSIP/synthetic DSIP | Modern clinical efficacy claims, current standard-of-care language, validated dosing, or contemporary safety assurances |
| Animal model | Rabbit, rat, cat, mouse, or other in-vivo DSIP experiments | Human treatment claims or route-equivalence claims |
| Mechanistic hypothesis | EEG, neurochemical, endocrine, receptor/signaling, stress, or biomarker observations | "Works by" language that implies a clinically established same-molecule mechanism |
| Anecdotal / commercial | Peptide-clinic marketing, influencer discussion, gray-market promotion | Any efficacy, safety, or regulatory claim |
Central honesty rule
Never convert older animal findings, historical exploratory human reports, or general DSIP biology into claims that current emideltide is clinically proven for insomnia, opioid withdrawal, stress, pain, or recovery in humans. [Kovalzon and Strekalova, 2006; Reuters, 2026].
Key studies and trials
| Study | Population | Endpoints | Results |
|---|---|---|---|
| Schoenenberger 1977 | Rabbits | Delta-EEG/sleep-related activity | Foundational evidence that established DSIP as a candidate sleep-related peptide in rabbit models |
| DSIP slow-wave/GH rat work | Rats | Slow-wave sleep and sleep-related GH release | Historical rat studies supported possible sleep-related biological activity, but not consistently across all models |
| Cat sleep-pattern study | Cats | Wakefulness/sleep architecture | Historical findings were mixed, reinforcing that DSIP's sleep effects are inconsistent across species and paradigms |
| Disturbed human sleep study | Adults with sleep disturbance | Sleep quality / architecture | Reported in the literature history, but not as a modern phase-based, well-powered development program; overall human evidence remains inconclusive |
| Isoflurane-adjunct anesthesia study | Adults receiving isoflurane anesthesia | BIS/EEG/heart-rate variability | Historical report described altered EEG/BIS and increased heart rate rather than straightforwardly deeper anesthesia |
| Opioid detoxification studies | Patients in opioid withdrawal/detox settings | Withdrawal symptom relief | Historical literature described symptomatic improvement, but current evidence quality is far below modern addiction-medicine standards |
| Metaphit seizure work | Rats | Seizure incidence / severity | Supported anticonvulsant interest in rodents |
| Phosphorylated DSIP analogue high-altitude memory study | Rodents | Sleep architecture, memory, p-CREB | Suggests some analogue-level experimental activity |
Purported benefits tagged by evidence strength
| Purported benefit | Evidence strength | What the evidence supports | What it does not support |
|---|---|---|---|
| Improves insomnia / deep sleep in humans | Historical human exploratory + animal model | Historical literature supports that DSIP has long been studied for sleep architecture and slow-wave-sleep biology | "Clinically proven insomnia treatment," "validated sleep peptide," or "established hypnotic" [Kovalzon and Strekalova, 2006; Reuters, 2026] |
| Helps opioid withdrawal | Historical human exploratory | Older reports described potential symptom relief in detox settings | "Evidence-based opioid-withdrawal treatment," "modern addiction-medicine therapy," or "standard clinical detox agent" [Kovalzon and Strekalova, 2006; Reuters, 2026] |
| Reduces stress / improves resilience | Animal model + mechanistic hypothesis | Historical preclinical literature supports stress-related and neuroendocrine interest | Generalized patient-facing claims of stress normalization or resilience therapy [Kovalzon and Strekalova, 2006] |
| Analgesic / pain support | Animal model | Historical rodent literature supports antinociceptive interest | Human pain-treatment claims [Kovalzon and Strekalova, 2006] |
| Anticonvulsant | Animal model | Historical rat studies support exploratory anticonvulsant activity | Human epilepsy-treatment claims [Kovalzon and Strekalova, 2006] |
| Anti-aging / longevity | Animal model | Mouse longevity/geroprotection signals have been described historically | Human healthy-aging, anti-aging, or life-extension claims [Kovalzon and Strekalova, 2006] |
| Clinically safe because it is endogenous | Anecdotal / commercial | Nothing here; endogenous-style framing explains interest, not safety | "Safe," "well tolerated," or "low-risk because natural" [Kovalzon and Strekalova, 2006; Reuters, 2026] |
Regulatory status
Reuters, The Guardian, and the Washington Post each report that FDA or a federal notice scheduled a July 23–24, 2026 PCAC meeting to review several peptides, with emideltide discussed on July 24 for opioid withdrawal and chronic insomnia. Reuters also reports that FDA staff documents released ahead of the meeting emphasized limited human evidence and safety/effectiveness concerns across the peptide set under review. [Reuters, 2026; The Guardian, 2026; Washington Post, 2026].
| Current working posture | Trigger for language update |
|---|---|
| Treat emideltide as an unapproved, investigational peptide. Do not describe it as FDA-approved, clinically proven, or established for insomnia or opioid withdrawal. Do not imply that current public attention resolves the evidence problem. | Public release of FDA briefing documents, committee recommendation, and any written FDA follow-on action after the July 2026 PCAC meeting. |
Operational and market considerations
Therapeutic indications and dosing/formulation
The only current indication language identified in authoritative contemporaneous reporting is the FDA-review framing of opioid withdrawal and chronic insomnia. That is review language, not approved labeling. No validated modern dose, route, schedule, or formulation standard was identified in this research pass. Historical DSIP studies used multiple experimental routes and paradigms, which is exactly why route/dose generalization should be avoided. [Reuters, 2026; Kovalzon and Strekalova, 2006].
Manufacturing and stability
Manufacturing risk is likely to be nontrivial for two reasons. First, DSIP/emideltide is a short peptide with historically described poor intrinsic stability. Second, any attempt to commercialize or compound it reliably would need modern control of identity, purity, degradants, aggregation/impurity profile, and formulation stability that is not demonstrated by the old literature. A rational CMC program would need modern peptide analytics, forced-degradation work, formulation screening, and rigorous release specifications before meaningful clinical translation. [Kovalzon and Strekalova, 2006; Reuters, 2026].
Intellectual property and key developers
The historical DSIP literature is old enough that the core peptide itself is unlikely to offer strong composition-of-matter exclusivity in most jurisdictions. The more plausible protectable assets would be formulations, modified analogs, delivery systems, specific manufacturing methods, or indication-specific clinical packages. In the currently visible U.S. context, the "developer" story is less a classic biotech program than a regulatory/compounding-market story. [Kovalzon and Strekalova, 2006; Reuters, 2026].
Market landscape and competitors
Emideltide is not competing from a position of clinical maturity. For insomnia, it would have to compete conceptually against a mature sleep-medicine market with far stronger evidence expectations; for opioid withdrawal, it would face a field where contemporary standards of evidence and treatment governance are especially high. Right now, its real competitive set is the gray-market / telehealth peptide conversation, not evidence-based mainstream therapeutics. That market context helps explain interest, but it should not be mistaken for validation. [Reuters, 2026; The Guardian, 2026].
Patient-side framing notes
Patients are likely to look at emideltide and think: it is a naturally occurring peptide, therefore it must be gentler or safer; it has "sleep" in the historical name, therefore it should help insomnia; it is being discussed by FDA, therefore it is probably on the verge of validation; it is used in peptide circles, therefore it must already "work." Those inferences are understandable, but nonetheless incorrect, and educational materials need to address these gaps. [The Guardian, 2026; Reuters, 2026].
Channel map
| Channel | Typical pitch | Evidence posture | Current examples |
|---|---|---|---|
| Peptide-policy / compounding coverage | Broader access, safer legal supply, innovation | Regulatory/process reporting, not efficacy proof | Reuters; Washington Post; The Guardian [Reuters, 2026; Washington Post, 2026; The Guardian, 2026] |
| Wellness / gray-market peptide discourse | Sleep, recovery, detox, anti-aging | Usually implication-heavy and evidence-light | Category-level reporting in The Guardian and Reuters [The Guardian, 2026; Reuters, 2026] |
| Historical scientific literature | Sleep biology, stress, endocrine signaling | Broad but inconsistent; mostly preclinical/older exploratory human work | Kovalzon review and legacy DSIP literature [Kovalzon and Strekalova, 2006] |
Legitimacy frame
The current legitimacy frame is not "this is proven." It is "this is an old neuropeptide with real science behind it, now finally getting regulatory attention." That framing is powerful because each piece is partly true. There really is historical literature. There really is current FDA-related attention. There really is public demand. But the omitted facts are the important ones: mechanism unresolved, PK underdefined, human evidence thin, and regulatory review not equal to approval. [Kovalzon and Strekalova, 2006; Reuters, 2026; The Guardian, 2026].
References & Citations
- Schoenenberger GA, Maier PF, Tobler HJ, Monnier M. A naturally occurring delta-EEG enhancing nonapeptide in rabbits – X. Final isolation, characterization and activity test. Pflügers Archiv. 1977;369(2):99-109.
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309.
- Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci U S A. 1988;85(10):3653-3656.
- Susić V, Masirević G, Totić S. The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat. Brain Res. 1987;414(2):262-270.
- Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981;37(9):913-917.
- Pomfrett CJ, Dolling S, Anders NR, Glover DG, Bryan A, Pollard BJ. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009;26(2):128-134.
- Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. 1983;10(4):205-208.
- Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371.
- Stanojlović O, Zivanović D, Mirković S, Mikhaleva I. Delta sleep-inducing peptide and its tetrapeptide analogue alleviate severity of metaphit seizures. Pharmacol Biochem Behav. 2004;77(2):227-234.
- Roy K, Chauhan G, Kumari P, et al. Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude. Life Sci. 2018;209:282-290.
- Reuters. US FDA to convene expert panel to review wider access to some peptides. April 15, 2026.
- Reuters. FDA staff question peptides backed by Kennedy ahead of advisory panel review. June 30, 2026.
- The Guardian. FDA to discuss easing restrictions on peptides despite safety concerns. June 26, 2026.
- Washington Post. Amid wellness craze, FDA weighs lifting peptide restrictions. April 15, 2026.
